Diasorin Spa Stock Fundamentals

34D Stock  EUR 104.05  0.95  0.90%   
DiaSorin SpA fundamentals help investors to digest information that contributes to DiaSorin SpA's financial success or failures. It also enables traders to predict the movement of DiaSorin Stock. The fundamental analysis module provides a way to measure DiaSorin SpA's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to DiaSorin SpA stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

DiaSorin SpA Company Current Valuation Analysis

DiaSorin SpA's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Enterprise Value

 = 

Market Cap + Debt

-

Cash

More About Current Valuation | All Equity Analysis

Current DiaSorin SpA Current Valuation

    
  8.48 B  
Most of DiaSorin SpA's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, DiaSorin SpA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Competition

In accordance with the recently published financial statements, DiaSorin SpA has a Current Valuation of 8.48 B. This is 40.93% lower than that of the Healthcare sector and 8.81% higher than that of the Diagnostics & Research industry. The current valuation for all Germany stocks is 48.97% higher than that of the company.

DiaSorin SpA Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining DiaSorin SpA's current stock value. Our valuation model uses many indicators to compare DiaSorin SpA value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across DiaSorin SpA competition to find correlations between indicators driving DiaSorin SpA's intrinsic value. More Info.
DiaSorin SpA is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about  0.46  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for DiaSorin SpA is roughly  2.20 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the DiaSorin SpA's earnings, one of the primary drivers of an investment's value.

DiaSorin Current Valuation Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DiaSorin SpA's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DiaSorin SpA could also be used in its relative valuation, which is a method of valuing DiaSorin SpA by comparing valuation metrics of similar companies.
DiaSorin SpA is currently under evaluation in current valuation category among its peers.

DiaSorin Fundamentals

About DiaSorin SpA Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze DiaSorin SpA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DiaSorin SpA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DiaSorin SpA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics tests for private and hospital analysis laboratories worldwide. DiaSorin S.p.A. was founded in 1968 and is headquartered in Saluggia, Italy. DIASORIN S operates under Diagnostics Research classification in Germany and is traded on Frankfurt Stock Exchange. It employs 1928 people.

Currently Active Assets on Macroaxis

Other Information on Investing in DiaSorin Stock

DiaSorin SpA financial ratios help investors to determine whether DiaSorin Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DiaSorin with respect to the benefits of owning DiaSorin SpA security.